New drug combo trial offers hope for aggressive lung cancer
NCT ID NCT07296809
Summary
This study aims to test the safety and early effectiveness of SKB500 drug combinations in people with extensive-stage small cell lung cancer. It will enroll 80 participants to see how well the treatment controls cancer growth and how long patients live without their disease getting worse. The trial is divided into two parts: first checking safety, then expanding to more patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.